| 1. |
- Andersson, Malin, et al.
(författare)
-
p Parametrization of physics-based battery models from input-output data : A review of methodology and current research
- 2022
-
Ingår i: Journal of Power Sources. - : Elsevier BV. - 0378-7753 .- 1873-2755. ; 521, s. 230859-
-
Forskningsöversikt (refereegranskat)abstract
- Physics-based battery models are important tools in battery research, development, and control. To obtain useful information from the models, accurate parametrization is essential. A complex model structure and many unknown and hard-to-measure parameters make parametrization challenging. Furthermore, numerous applications require non-invasive parametrization relying on parameter estimation from measurements of current and voltage. Parametrization of physics-based battery models from input-output data is a growing research area with many recent publications. This paper aims to bridge the gap between researchers from different fields that work with battery model parametrization, since successful parametrization requires both knowledge of the underlying physical system as well as understanding of theory and concepts behind parameter estimation. The review encompasses sensitivity analyses, methods for parameter optimization, structural and practical identifiability analyses, design of experiments and methods for validation as well as the use of machine learning in parametrization. We highlight that not all model parameters can accurately be identified nor are all relevant for model performance. Nonetheless, no consensus on parameter importance could be shown. Local methods are commonly chosen because of their computational advantages. However, we find that the implications of local methods for analysis of non-linear models are often not sufficiently considered in reviewed literature.
|
|
| 2. |
- Bjerkvig, Rolf, et al.
(författare)
-
Cancer stem cells and angiogenesis
- 2009
-
Ingår i: Seminars in Cancer Biology. - London : Academic Press. - 1044-579X .- 1096-3650. ; 19:5, s. 279-284
-
Forskningsöversikt (refereegranskat)abstract
- Most cancers contain tumor cells that display stem cell-like characteristics. How and when such cells appear in tumors are not clear, but may involve both stochastic as well as hierarchical events Most. likely, tumor cells that display stem cell-like characteristics can undergo asymmetric cell division giving rise to tumor cells that trigger angiogenic programs. As normal stem cells the cancer stem-like cells seem to adapt to hypoxic environments and will use metabolic pathways that involve increased conversion of glucose to pyruvate and lactate, and a concomitant decrease in mitochondrial metabolism and mitochondrial mass. The molecular pathways responsible for inducing glycolysis are now being explored. These pathways seem to mediate multiple metabolic functions in cancer stem-like cells, leading to a highly migratory and angiogenesis-independent phenotype. Future challenges will be to identify and validate molecular targets involved in anaerobic metabolic pathways active in cancer stem-like cells and to determine how these pathways differ from regulatory pathways involved in normal stem cell function.
|
|
| 3. |
- de Jager, Vincent D., et al.
(författare)
-
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
- 2024
-
Ingår i: The Lancet Regional Health. - : Elsevier. - 2666-7762. ; 38
-
Forskningsöversikt (refereegranskat)abstract
- In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control.
|
|
| 4. |
- Franks, P. W., et al.
(författare)
-
Technological readiness and implementation of genomic-driven precision medicine for complex diseases
- 2021
-
Ingår i: Journal of Internal Medicine. - : Wiley. - 0954-6820 .- 1365-2796. ; 290:3, s. 602-620
-
Forskningsöversikt (refereegranskat)abstract
- The fields of human genetics and genomics have generated considerable knowledge about the mechanistic basis of many diseases. Genomic approaches to diagnosis, prognostication, prevention and treatment - genomic-driven precision medicine (GDPM) - may help optimize medical practice. Here, we provide a comprehensive review of GDPM of complex diseases across major medical specialties. We focus on technological readiness: how rapidly a test can be implemented into health care. Although these areas of medicine are diverse, key similarities exist across almost all areas. Many medical areas have, within their standards of care, at least one GDPM test for a genetic variant of strong effect that aids the identification/diagnosis of a more homogeneous subset within a larger disease group or identifies a subset with different therapeutic requirements. However, for almost all complex diseases, the majority of patients do not carry established single-gene mutations with large effects. Thus, research is underway that seeks to determine the polygenic basis of many complex diseases. Nevertheless, most complex diseases are caused by the interplay of genetic, behavioural and environmental risk factors, which will likely necessitate models for prediction and diagnosis that incorporate genetic and non-genetic data.
|
|
| 5. |
- Johansson, Mikael, 1969
(författare)
-
Nano Culture
- 2010
-
Ingår i: Encyclopedia of Nanoscience and Society. ; , s. 462-463
-
Forskningsöversikt (refereegranskat)
|
|
| 6. |
- Johansson, Mikael, 1969
(författare)
-
Technological utopia
- 2011
-
Ingår i: The Sage reference series on green society: toward a sustainable future. ; 10:Technology, s. 408-409
-
Forskningsöversikt (refereegranskat)
|
|
| 7. |
- Johansson Wensman, Jonas, et al.
(författare)
-
Borna disease virus infection in cats
- 2014
-
Ingår i: Veterinary Journal. - : Elsevier BV. - 1090-0233 .- 1532-2971. ; 201, s. 142-149
-
Forskningsöversikt (refereegranskat)abstract
- Bornaviruses are known to cause neurological disorders in a number of animal species. Avian Bornavirus (ABV) causes proventricular dilatation disease (PDD) in birds and Borna disease virus (BDV) causes Borna disease in horses and sheep. BDV also causes staggering disease in cats, characterised by ataxia, behavioural changes and loss of postural reactions. BDV-infection markers in cats have been reported throughout the world. This review summarizes the current knowledge of Borna disease viruses in cats, including etiological agent, clinical signs, pathogenesis, epidemiology and diagnostics, with comparisons to Bornavirus infections in other species.
|
|
| 8. |
- Johnson, Hannes, 1982, et al.
(författare)
-
Will the Ship Energy Efficiency Management Plan reduce CO2 emissions? A comparison with ISO 50001 and the ISM Code
- 2013
-
Ingår i: Maritime Policy and Management. - : Informa UK Limited. - 0308-8839 .- 1464-5254. ; 40:2, s. 177-190
-
Forskningsöversikt (refereegranskat)abstract
- The IMO Ship Energy Efficiency Management Plan (SEEMP) is the sole international regulatory instrument expected to affect rising CO2 emissions from shipping in the short-term. In this article, we discuss present gaps in the SEEMP guidelines through a comparison with the international standard for energy management systems, ISO 50001, and with the International Safety Management (ISM) Code, which sets requirements for safety management systems in shipping companies. We show that the SEEMP lacks crucial features found in typical management system standards, such as requirements on policy and management reviews. Moreover, best-practice in the form of the ISO 50001 addresses important aspects, such as monitoring, energy auditing, design, and procurement processes in much more detail. In the context of previous research on these instruments and on energy efficiency in general, we argue that these gaps may be detrimental to the success of the SEEMP, both from the societal perspective of CO2 abatement and from the perspective of companies’ success in energy management. This requires further attention by academia, policy-makers and industry.
|
|
| 9. |
- Köhn, Linda, et al.
(författare)
-
Liquid biopsies in lung cancer : time to implement research technologies in routine care?
- 2017
-
Ingår i: Annals of Translational Medicine. - : AME Publishing Company. - 2305-5839 .- 2305-5847. ; 5:13
-
Forskningsöversikt (refereegranskat)abstract
- Lung cancer is the leading cause of cancer mortality. A substantial progress in the understanding of lung cancer biology has resulted in several promising targeted therapies for advanced disease. Druggable targets today include point mutations such as EGFR, BRAF and re-arrangements in genes such as ALK and ROS1. Liquid biopsies collecting e.g., circulating tumor DNA (ctDNA) reflects overall tumor information and is not biased by analyzing of only a small fraction of the tumor and is always accessible in contrast to the lung cancer tissue. Technological advances in detection of low frequency mutation variants in ctDNA have made it the dominating liquid biopsy platform in terms of utility and sensitivity. Circulating DNA or RNA may possible be used to define populations with higher risk of developing lung cancer, thus reducing screening cohorts and increasing the positive predictive value of screening. Blood based-tests may also aid to identify genetic alterations several weeks prior to radiologically verified recurrence and may be of great value in the follow-up of lung cancer patients. Besides being an alternative to invasive biopsies in selected cases, liquid biopsies offer a unique possibility to monitor treatment response following medical treatment as well as treatment response and resistance development after targeted therapy, giving a possibility to modify the treatment after the genetic profile of the tumor. Ideally, genetic alterations found in ctDNA could be tracked in real-time discriminating between fast-growing life-threatening tumors from more indolent slow growing tumors or premalignant growth that are of no concern for the wellbeing of the patient. This review focuses on future perspectives of liquid biopsies in lung cancer care for different clinical settings and present current technological platforms for further discussion of possible strategies for implementation of liquid biopsies in lung cancer.
|
|
| 10. |
- Miletic, Hrvoje, et al.
(författare)
-
Anti-VEGF therapies for malignant glioma : treatment effects and escape mechanisms
- 2009
-
Ingår i: Expert opinion on therapeutic targets. - : Taylor & Francis. - 1472-8222 .- 1744-7631. ; 13:4, s. 455-468
-
Forskningsöversikt (refereegranskat)abstract
- Background: Glioblastoma multiforme (GBM) has a very poor prognosis and novel treatment strategies are urgently needed. GBM appears to be an optimal target for anti-angiogenic therapy as the tumour shows a high degree of endothelial cell proliferation and pro-angiogenic growth factor expression. Objective: To examine the role of angiogenic factors (particularly VEGF) in glioma and whether inhibition of these factors can be used as a treatment.Methods: A review of relevant literature.Results/conclusions: Anti-angiogenic therapy has fulfilled the proof of concept in glioma animal models. In glioma patients, the efficacy of anti-angiogenic mono-therapies initially has been disappointing. However recent clinical trials combining bevacizumab, an anti-VEGF antibody, with chemotherapy reported very encouraging response rates. Although randomized phase III clinical trials with anti-angiogenic molecules are not yet available for GBM patients, this treatment regimen is already applied off protocol in several clinical centers. It should be kept in mind though that tumours can develop escape mechanisms. In particular invasive cells, which migrate away from the highly vascularized tumour core, are not targeted by anti-angiogenic therapies. In our opinion, the future of anti-angiogenic therapy will rely on a combination strategy including chemotherapy and drugs that target invasive glioma cells.
|
|
